Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Protein Kinase Inhibitors/administration & dosage"" wg kryterium: Temat


Wyświetlanie 1-18 z 18
Tytuł :
Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms:minimal residual disease and cure?
Autorzy :
Hasselbalch, Hans Carl
Holmström, Morten Orebo
Pokaż więcej
Temat :
Protein Kinase Inhibitors/administration & dosage
Inflammation/diagnosis
Cure
Disease Progression
DNA-hypomethylator
Polycythemia Vera/diagnosis
hemic and lymphatic diseases
Inflammation
Review
Pegylated interferon-alpha2
Combination therapy
MPNs
Ruxolitinib
MRD
Myeloproliferative neoplasms
Myeloproliferative Disorders/diagnosis
Immunologic Surveillance
MPN
Treatment Outcome
Mutation
Vaccination strategies
Neoplasm, Residual
Statins
Minimal residual disease
Journal Article
Humans
Interferon-alpha/administration & dosage
Źródło :
Seminars in Immunopathology
Hasselbalch, H C & Holmström, M O 2019, ' Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms : minimal residual disease and cure? ', Seminars in Immunopathology, vol. 41, no. 1, pp. 5-19 . https://doi.org/10.1007/s00281-018-0700-2
Opis pliku :
application/pdf
Tytuł :
Clinical aspects and perspectives of erlotinib in the treatment of patients with biliary tract cancer
Autorzy :
Jensen, Lars Henrik
Pokaż więcej
Temat :
Anticancer treatment
Biliary tract cancer
Clinical value
Erlotinib
Molecularly targeted agents
Palliative care
Bevacizumab/administration & dosage
Humans
Erlotinib Hydrochloride/administration & dosage
Molecular Targeted Therapy
Disease-Free Survival
Protein Kinase Inhibitors/administration & dosage
Animals
Biliary Tract Neoplasms/drug therapy
Drug Design
Antineoplastic Combined Chemotherapy Protocols/administration & dosage
Źródło :
Jensen, L H 2016, ' Clinical aspects and perspectives of erlotinib in the treatment of patients with biliary tract cancer ', Expert Opinion on Investigational Drugs, vol. 25, no. 3, pp. 359-365 . https://doi.org/10.1517/13543784.2016.1142973
Tytuł :
Subconjunctival injection of XG-102, a c-Jun N-terminal kinase inhibitor peptide, in the treatment of endotoxin-induced uveitis in rats
Autorzy :
El Zaoui, I.
Touchard, E.
Berdugo, M.
Abadie, C.
Kowalczuk, L.
Deloche, C.
Zhao, M.
Naud, M.C.
Combette, J.M.
Behar-Cohen, F.
Pokaż więcej
Temat :
Protein Kinase Inhibitors/administration & dosage
Uveitis/metabolism
Proto-Oncogene Proteins c-jun/metabolism
Anti-Inflammatory Agents/administration & dosage
Chemokine CXCL1/biosynthesis
Uveitis/drug therapy
Uveitis/chemically induced
Proto-Oncogene Proteins c-jun/antagonists & inhibitors
Phosphorylation/drug effects
Down-Regulation/drug effects
Nitric Oxide Synthase Type II/biosynthesis
Peptides/administration & dosage
Źródło :
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association For Ocular Pharmacology and Therapeutics 31(1) 17-24
Journal of Ocular Pharmacology and Therapeutics, vol. 31, no. 1, pp. 17-24
Opis pliku :
application/pdf
Tytuł :
High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib
Autorzy :
Kuiper, J.L.
Heideman, D.A.M.
Thunnissen, E.
van Wijk, A.W.
Postmus, P.E.
Smit, E.F.
Pokaż więcej
Temat :
Antineoplastic Agents/administration & dosage
Protein Kinase Inhibitors/administration & dosage
Meningeal Neoplasms/drug therapy
Erlotinib Hydrochloride
Quinazolines/administration & dosage
Disease Progression
ErbB Receptors/genetics
Lung Neoplasms/drug therapy
Humans
Carcinoma, Non-Small-Cell Lung/drug therapy
Źródło :
European Journal of Cancer, 50(7), 1399 - 401. Pergamon
Tytuł :
A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma
Autorzy :
Renner, C.
Zinzani, P.L.
Gressin, R.
Klingbiel, D.
Dietrich, P.Y.
Hitz, F.
Bargetzi, M.
Mingrone, W.
Martinelli, G.
Trojan, A.
Bouabdallah, K.
Lohri, A.
Gyan, E.
Biaggi, C.
Cogliatti, S.
Bertoni, F.
Ghielmini, M.
Brauchli, P.
Ketterer, N.
Pokaż więcej
Temat :
refractory
TOR Serine-Threonine Kinases/antagonists & inhibitors
Neoplasm Staging
610 Medicine & health
Remission Induction
Drug Administration Schedule
everolimus
Sirolimus/administration & dosage/adverse effects/analogs & derivatives
Protein Kinase Inhibitors/administration & dosage/adverse effects
mantle cell lymphoma
Neoplasm Proteins/antagonists & inhibitors
Female
Clinic for Oncology and Hematology
ddc:616
Original Articles and Brief Reports
Aged
Middle Aged
Recurrence
RAD001
Lymphoma, Mantle-Cell/drug therapy/mortality
Disease-Free Survival
Prospective Studies
relapsed
Adult
Aged, 80 and over
Humans
Male
Źródło :
Haematologica, vol. 97, no. 7, pp. 1085-1091
Renner, C; Zinzani, P L; Gressin, R; Klingbiel, D; Dietrich, P Y; Hitz, P; Bargetzi, M; Mingrone, W; Martinelli, G; Trojan, A; Bouabdallah, K; Lohri, A; Gyan, E; Biaggi, C; Cogliatti, S; Bertoni, F; Ghielmini, M; Brauchli, P; Ketterer, N (2012). A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica, 97(7):1085-1091.
Haematologica, Vol. 97, No 7 (2012) pp. 1085-91
Opis pliku :
application/pdf; STAMPA
    Wyświetlanie 1-18 z 18

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies